Teladoc Health (NYSE:TDOC) Announces Quarterly Earnings Results
by Doug Wharley · The Cerbat GemTeladoc Health (NYSE:TDOC – Get Free Report) posted its quarterly earnings data on Wednesday. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02), FiscalAI reports. The business had revenue of $613.85 million during the quarter, compared to the consensus estimate of $613.82 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The business’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.53) EPS. Teladoc Health updated its FY 2026 guidance to -1.050–0.750 EPS and its Q2 2026 guidance to -0.300–0.200 EPS.
Here are the key takeaways from Teladoc Health’s conference call:
- Consolidated results beat guidance — Q1 revenue $614M and adjusted EBITDA $58M, with $751M in cash and net debt/adjusted EBITDA below 0.9x, signaling near-term financial strength.
- Integrated Care showed steady growth and margin expansion — revenue $395M (+1.5% YoY) and adjusted EBITDA $56M (14.2% margin); management expects the shift from subscriptions to visit-based care and new AI-enabled, enhanced 24/7 offerings to become a net tailwind in H2.
- BetterHelp insurance rollout is ahead of plan — live in 30 states + DC, >6,000 credentialed providers, >150M insured lives, and insurance sessions >14,000/week; company now expects to exit 2026 with a BetterHelp insurance run-rate of at least $125M.
- BetterHelp’s direct-to-consumer business remains pressured — Q1 revenue declined 9% YoY to $218M, average paying users fell 9%, and adjusted EBITDA was only $2M (0.9% margin) as cash-pay weakness and insurance-scaling investments weighed on profitability.
- Management reiterated full-year 2026 guidance (revenue $2.48B–$2.58B; adj EBITDA $267M–$306M; FCF $130M–$170M), plans a two-phase approach to reduce 2027 convertible-related gross debt, and expects stock-based comp to fall below $55M, indicating disciplined capital and cost management.
Teladoc Health Price Performance
Shares of NYSE:TDOC traded down $0.05 during midday trading on Wednesday, hitting $5.95. The stock had a trading volume of 5,384,618 shares, compared to its average volume of 5,914,556. The company’s 50-day moving average price is $5.37 and its 200-day moving average price is $6.47. The company has a market capitalization of $1.07 billion, a P/E ratio of -5.22 and a beta of 2.07. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.77.
More Teladoc Health News
Here are the key news stories impacting Teladoc Health this week:
- Positive Sentiment: Q1 revenue broadly matched estimates: first-quarter revenue was $613.8M (down 2% YoY) and essentially in line with the consensus, indicating stable top-line demand. Teladoc Health Reports First Quarter 2026 Results
- Neutral Sentiment: Guidance updated: Q2 FY2026 EPS range set at -$0.30 to -$0.20 (consensus ~ -$0.22) and revenue guidance $597M–$626M (consensus ~$623.9M). Full-year revenue guidance $2.5B–$2.6B (in line with consensus) while FY EPS was guided to -$1.05 to -$0.75 (below consensus). The revenue outlook is steady, but EPS ranges are wide. Teladoc Health Reports First Quarter 2026 Results
- Negative Sentiment: Q1 EPS missed and loss widened: Teladoc reported a $0.36 loss per share vs. analyst consensus of ~$0.34 (Zacks noted a $0.32 estimate) and a larger loss than a year ago, highlighting ongoing profitability pressure. Teladoc (TDOC) Reports Q1 Loss, Beats Revenue Estimates
- Negative Sentiment: Profitability metrics remain weak: Q1 net loss (~$63.8M), negative net margin (~-7.9%) and negative ROE (~-9.1%) underline that operating leverage and margin recovery are still a work in progress—key risks for valuation until EPS path clearer. Q1 Press Release / Supplement
Insider Activity at Teladoc Health
In other news, CEO Charles Divita III sold 27,731 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total value of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares in the company, valued at approximately $2,002,664.16. The trade was a 7.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.70% of the company’s stock.
Hedge Funds Weigh In On Teladoc Health
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Creative Planning raised its position in shares of Teladoc Health by 7.7% in the 3rd quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock valued at $159,000 after buying an additional 1,462 shares in the last quarter. Syon Capital LLC raised its position in shares of Teladoc Health by 19.1% in the 4th quarter. Syon Capital LLC now owns 14,140 shares of the health services provider’s stock valued at $99,000 after buying an additional 2,264 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after buying an additional 2,810 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Teladoc Health by 19.2% in the 4th quarter. HighTower Advisors LLC now owns 18,647 shares of the health services provider’s stock valued at $131,000 after buying an additional 2,997 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Teladoc Health by 2.0% in the 2nd quarter. California State Teachers Retirement System now owns 158,537 shares of the health services provider’s stock valued at $1,381,000 after buying an additional 3,114 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have issued reports on TDOC. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a report on Friday, March 27th. Barclays cut their price objective on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Piper Sandler reissued an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Stifel Nicolaus cut their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.62.
Check Out Our Latest Research Report on TDOC
Teladoc Health Company Profile
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.